Author:
Ernst Moritz,Dührsen Ulrich,Hellwig Dirk,Lenz Georg,Skoetz Nicole,Borchmann Peter
Publisher
Deutscher Arzte-Verlag GmbH
Reference32 articles.
1. SEER: Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database. National Cancer Institute, DCCPS, Surveillance Research Program 2018.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–76.
3. Coiffier B, Thieblemont C, Van Den Neste E, et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d‘Etudes des Lymphomes de l‘Adulte. Blood 2010; 116: 2040–5.
4. Cunningham D, Hawkes EA, Jack A, et al.: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381: 1817–26.
5. Alaggio R, Amador C, Anagnostopoulos I, et al.: The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720–48.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献